Abstract 2789
Background
The Catalan Institute of Oncology (ICO) is a specialised cancer institution. It has four centres distributed around Catalonia that covers 45% of the adult cancer patient population in the autonomy. In three of them exists a radiotherapy department: L’Hospitalet, Badalona and Girona; with 11 accelerators altogether. Near 6.000 patients per year receive treatment in them. All radiotherapy departments in Spain need to accomplish with a quality system. ICO has a system based in International Organization for Standardization (ISO) regulations. Recently, a new system of ISO certification (ISO 9001:2015) has required increasing the homogenization level among our three departments. In addition, ICO promotes equality in access to services and assistance. For all these reasons it was developed the “Standardize project of the assistance procedures in Oncologic radiation”.
Methods
The ISO whole process was divided in 6 sub processes. In each center there was a group of professionals who works with every sub process and discuss with the other hospitals in order to define the common procedures. In February 2018, we started a work plan to do it through teleconference meetings. Nurses and radiotherapist technicians were included and nominate several leaders in each of the working groups which involved their activity. Meeting works ended in June 2018. From then until 2019 July we run with the implementation time.
Results
Nurses and radiotherapist technicians of the three institutions defined the list of agreements and consensus to do: homogeneous written education for patients to implement the active identification with patients Image guided radiotherapy protocols (IGRT) protocols for management break on treatments & short interruptions safety check list for the first session patient follow-up, alternating nurses and physicians nurse appointment at the end of treatments quality indicators for activity & schedules.
Conclusions
This project has assured that population from 3 different areas will receive same treatments, under equal circumstances. We incorporated strengths of each centre, using now a unique map of the process of radiotherapy. Furthermore we share same safety and prevention standards and a prospective system for risk analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Català d’Oncologia.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2171 - CCND1 Amplification Contributes to Immunosuppression in Head and Neck Squamous Cell Carcinoma and the Association with a Poor Response to Immune Checkpoint Inhibitors
Presenter: Chloe Huang
Session: Poster Display session 3
Resources:
Abstract
2624 - Efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer patients with sensitive genes mutation
Presenter: Hui-Juan Cui
Session: Poster Display session 3
Resources:
Abstract
3494 - Neutrophil to Lymphocyte Ratio (NLR) kinetics as predictors of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (NSCLC) patients treated with nivolumab (N).
Presenter: Audrey Simonaggio
Session: Poster Display session 3
Resources:
Abstract
3964 - Predictive markers of checkpoint inhibitor activity in adult metastatic solid tumours
Presenter: Alexandra Pender
Session: Poster Display session 3
Resources:
Abstract
3041 - Blood-based TMB (bTMB) correlates with tissue-based TMB (tTMB) in a multi-cancer Phase I IO Cohort
Presenter: Daniel Araujo
Session: Poster Display session 3
Resources:
Abstract
3910 - Analysis of Molecular Profile Complexities for Immunotherapy Decision Support
Presenter: Robert Dóczi
Session: Poster Display session 3
Resources:
Abstract
4836 - The Role of Tumor Neoantigens in the Differential Response to Immunotherapy (IO) in EGFR and BRAF Mutated Lung Cancers - Quantity or Quality?
Presenter: Katrina Case
Session: Poster Display session 3
Resources:
Abstract
1929 - Impact of previous corticosteroid (CS) exposure on efficacy of Programmed Cell Death-(Ligand) 1 blockade in patients with advanced Non-Small-Cell Lung Cancer (NSCLC): a single Center retrospective analysis
Presenter: Fabrizio Nelli
Session: Poster Display session 3
Resources:
Abstract
2601 - Comparison 18F-FDG-PET/CT criteria for prediction of therapy response and clinical outcome in patients with metastatic melanoma treated with Ipilimumab and PD-1 inhibitors
Presenter: Sabrina Vari
Session: Poster Display session 3
Resources:
Abstract
3628 - Predictive model for survival in advanced non-small-cell lung cancer (NSCLC) treated with frontline pembrolizumab
Presenter: Xabier Mielgo Rubio
Session: Poster Display session 3
Resources:
Abstract